Somerville, MA — Sept 24, 2024
Combining AI innovation with pharma expertise to accelerate drug development and tackle complex diseases.
Partnership Overview:
Novartis and Generate:Biomedicines have entered a transformative collaboration with the goal of leveraging advanced artificial intelligence (AI) and machine learning (ML) technologies to revolutionize protein drug discovery. This up-to-$1 billion partnership aims to enhance therapeutic development for diverse, yet unspecified, disease areas by utilizing Generate’s cutting-edge platform alongside Novartis’ deep expertise in biologics, clinical research, and manufacturing.
Strategic Collaboration Highlights:
AI-Driven Innovation in Protein Design: Generate’s proprietary platform uses generative biology and machine learning algorithms to design novel protein molecules, including antibodies targeting specific epitopes and functional proteins. This collaboration focuses on advancing protein-based therapies with a higher success rate and reduced discovery timelines.
Accelerating Therapeutic Development: By integrating Generate’s AI-powered platform with Novartis’ extensive clinical and disease biology expertise, this partnership aims to create new protein therapeutics faster and more cost-effectively than traditional drug development methods, addressing complex and poorly understood disease targets.
Target Agnostic and Modular Approach: Generate’s platform is designed to be agnostic to both disease areas and protein modalities. This flexibility allows the collaboration to target a wide array of diseases—from oncology to neuroscience—by harnessing relevant expertise to optimize protein-based therapeutics.
Value Proposition and Financial Terms:
The collaboration includes an upfront payment of $65 million, including $15 million toward equity investment in Generate, with an additional $1 billion in potential milestone payments tied to the successful development of protein therapeutics. Additionally, Generate stands to receive tiered royalties upon commercialization of any resulting therapeutics.
Technological Synergy:
Generative Biology Platform: Generate’s platform leverages AI and machine learning to analyze vast protein sequence datasets and discover new proteins that could be used in therapeutics, dramatically increasing drug discovery speed while minimizing the risks associated with traditional approaches.
Integration of Novartis Expertise: Novartis brings critical experience in disease target biology, clinical development, and manufacturing, which complements Generate’s innovations in protein molecular design. This fusion of expertise enables the rapid and scalable development of novel therapeutics.
Strategic Alignment and Vision:
This partnership aligns with Novartis’ ongoing commitment to integrating AI into drug discovery, building on its prior collaborations with tech leaders like Microsoft to enhance medicinal chemistry through generative AI. Generate’s innovative platform will serve as a key enabler in achieving Novartis’ vision of an AI-driven drug discovery process.
Leadership Insights:
Michael Nally, CEO of Generate:Biomedicines, stated, “This collaboration is the perfect synergy of expertise in AI, molecular biology, and drug development. With Novartis’ deep clinical insights and our generative biology technology, we are well-positioned to address some of the most challenging medical problems and deliver breakthrough therapeutics.”
Long-Term Impact and Industry Disruption:
As AI-driven drug discovery transforms the pharmaceutical landscape, this partnership sets the stage for groundbreaking advances in personalized medicine. By unlocking new therapeutic possibilities and optimizing the drug development process, Novartis and Generate aim to deliver significant value to patients, investors, and the broader healthcare ecosystem.
Summary:
This strategic collaboration between Generate:Biomedicines and Novartis has the potential to redefine the future of protein therapeutics. By combining cutting-edge AI capabilities with decades of pharma expertise, the companies are positioned to accelerate drug development, reduce costs, and bring novel therapies to market faster, benefitting both patients and stakeholders alike.
By
